Neurology March 10, 2023 QurAlis raises funds to develop neurodegenerative disease medicines By PBR Staff Writer The financing round, which brings the total funds raised by the firm to $143.5m, was led by EQT Life Sciences, investing from Droia Ventures, Sanofi Ventures and the
Drug Discovery March 9, 2023 invoX Pharma completes acquisition of F-star Therapeutics for $161m By PBR Staff Writer F-star is being acquired for a total cash consideration of approximately $161m or $7.12 per share. Currently, F-star is undertaking Phase II trials in Europe and the US.
Oncology March 8, 2023 Volastra in-licenses Amgen’s KIF18A inhibitor sovilnesib By PBR Staff Writer Under the agreement terms, Volastra receives an exclusive global license (ex-China) for the development and commercialisation of sovilnesib. Amgen will, in exchange, receive an upfront mix of cash
Ophthalmology March 7, 2023 Selagine, Grifols agree to develop, commercialise immunoglobulin eye drops By PBR Staff Writer Selagine is a spin-out company from the University of Illinois at Chicago (UIC), while Grifols is a provider of plasma-derived medicines. A biologic drug, an immunoglobulin eye drop
Central Nervous System March 6, 2023 Ractigen receives orphan drug designation for ALS therapy By PBR Staff Writer RAG-17 has been designed to act on and knockdown SOD1 expression in patients with pathogenic mutations that are known to cause ALS. The chemistry of the therapeutic is
Neurology March 3, 2023 Avenue signs license agreement with AnnJi Pharmaceutical for AJ201 By PBR Staff Writer Designed to modify SBMA through several mechanisms, AJ201 is currently in a Phase Ib/IIa study in the US to treat spinal and bulbar muscular atrophy (SBMA), which is
Other Diseases March 2, 2023 Nexus Pharmaceuticals gets FDA approval for Emerphed pre-filled syringe By PBR Staff Writer The company claimed that its 10mL presentation is the only FDA-approved ready-to-administer 10mL pre-filled syringe available. Nexus Pharmaceuticals CEO and president Usman Ahmed said: “We are pleased to
Drug DiscoveryResearch & Development March 1, 2023 Tempus, Pfizer partner for cancer drug development By PBR Staff Writer Under the collaboration, both the companies will work together for further AI and machine learning-driven efforts in therapeutic development. The partnership aims to gather insights more precisely that
RegulationApprovals February 28, 2023 AbbVie gets positive CHMP opinion for upadacitinib to treat Crohn’s disease in adults By PBR Staff Writer Upadacitinib (RINVOQ, 45mg [induction dose] and 15mg and 30mg [maintenance doses]) is intended for those patients who have not shown adequate response, lost response or were intolerant to
Skin RashDrug Manufacturing February 27, 2023 Timber’s TMB-001 receives orphan drug designation from EC to treat XLRI By PBR Staff Writer Earlier, TMB-001 received orphan drug designation from the EC to treat autosomal recessive congenital ichthyosis (ARCI). Timber Pharmaceuticals chairman and CEO John Koconis said: “We are pleased to